Zitter Health Insights Access Answered.

Managed Markets Insights

Perspectives on Medical Therapy Access, Reimbursement and Payer Influences

Trends in Psoriasis Payer Management

The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. The newest entrant into the psoriasis market, Novartis’ Cosentyx, was …

Read Post

Drivers of Rheumatoid Arthritis Prescription Abandonment

Patient prescription abandonment and medication non-adherence is a major market concern, with estimates of up to one-third of written prescriptions not being filled and projected costs of $290 billion each year from non-adherence1. While more traditional research focuses on prescription fill rates, the Abandonment Insight …

Read Post

Biosimilars in Rheumatoid Arthritis: What to Expect?

Rheumatoid arthritis (RA) has traditionally been one of the more competitive markets for new entrants with the TNF-alpha inhibitor class of drugs enjoying a good percentage of the market share. By effectively inhibiting the response to tumor necrosis factor (TNF), a cytokine released during …

Read Post

Impact of the entrance of PCSK9i to the hypercholesterolemia market in Q3 2015

Amgen and Regeneron/Sanofi are in a heated race to launch their respective PCSK9 inhibitors (PCSK9i), Repatha and Praluent, late this summer. These new drugs are highly efficacious, reducing LDL cholesterol levels up to an additional 60%, and tout a low instance of adverse events. …

Read Post